Study: Daiichi Sankyo's anticoagulant outperforms standard treatment

Data on more than 8,000 patients with venous thromboembolism showed that those who received Daiichi Sankyo's anticoagulant drug edoxaban had fewer cases of bleeding than those who received warfarin. The drug also appeared to be safer than standard treatment and works best for patients with more severe conditions, researchers reported in the New England Journal of Medicine.

View Full Article in:

Wall Street Journal (tiered subscription model), The · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Chicago, IL
Manager, Business Conduct
Foster City, CA
Product Patent Attorney
Foster City, CA
Employment Counsel
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC